

Presentation: Image: Français
1 of 1[View Images](#)**(21) Int. PCT/US99/24756**
Application
Number:**(22) Int.** 22 October 1999
Filing Date: (22.10.1999)**(30) Priority Data**09/177,546 22 October US
1998
(22.10.1998)**(71) Applicant:**IDUN
PHARMACEUTICALS,
INC. Suite 300, 11085
North Torrey Pines Road,
La Jolla, CA 92037 ; (US).
[US/US]. *(for all*
designated states except
*US)***(72) Inventors; and****(75) Inventors/Applicants:**KARANEWSKY, Donald,
S. 1797 Continental Lane,
Escondido, CA 92029 ;
(US) [US/US]. KALISH,
Vincent, J. 344 Dubois
Road, Annapolis, MD
21401 ; (US) [US/US].
ROBINSON, Edward, D.
3567 Tony Drive, San
Diego, CA 92122 ; (US)
[US/US]. ULLMAN,
Brett, R. 4021 Richmond
Street #6, San Diego, CA
92103 ; (US) [US/US].**(74) Agent:**HERMANN, Karl, R.
Seed and Berry LLP, 6300
Columbia, 701 Fifth
Avenue, Seattle, WA
98104–7092 ; (US).**(51) International**
Patent
Classification⁷:C07C 237/22,
C07D 211/60,
217/26, 209/42,
215/233,
213/64, 277/10,
A61K 31/195,
31/33

A1

(11) Int.
Publication **WO 00/23421**
Number:**(43) Int.**
Publication 27 April 2000
Date: (27.04.2000)**(54) Title:**(SUBSTITUTED)ACYL DIPEPTIDYL
INHIBITORS OF THE ICE/ced–3 FAMILY
OF CYSTEINE PROTEASES

No Image Available.

(57) Abstract

This invention is directed to novel (substituted)acyl

(81) Designated States:

AE, AL, AM, AT, AU,
AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM,
EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP,
KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU,
ZA, ZW ; ARIPO patent
(GH, GM, KE, LS, MW,
SD, SL, SZ, TZ, UG,
ZW); Eurasian patent
(AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM);
European patent (AT, BE,
CH, CY, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE); OAPI
patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW,
ML, MR, NE, SN, TD,
TG)

Published

*With international search
report.*

*Before the expiration of
the time limit for amending
the claims and to be
republished in the event of
the receipt of amendments.*

dipeptidyl ICE/ced–3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

**Presentation:**

Gazette

**Image:**

Small



Français



1 of 1